

PRODUCT MONOGRAPH

^NULTIVA[®]

(Remifentanil Hydrochloride)

1 mg/vial, 2 mg/vial, 5 mg/vial Injection

Opioid Component to Anesthesia

Abbott Laboratories, Limited
8401 Trans Canada Highway
St-Laurent (QC) CANADA H4S 1Z1

Date of Preparation:
October 12, 1999

Date of the Previous Revision:
February 16, 2000

Date of Revision:
January 8, 2009

Submission Control No: 123891

NOTE: ULTIVA is a trademark of the Glaxo group of companies, Abbott Laboratories Limited licensed use

Table of Contents

PART I: HEALTH PROFESSIONAL INFORMATION.....3
SUMMARY PRODUCT INFORMATION3
INDICATIONS AND CLINICAL USE.....3
CONTRAINDICATIONS4
WARNINGS AND PRECAUTIONS.....4
ADVERSE REACTIONS.....8
DRUG INTERACTIONS10
DOSAGE AND ADMINISTRATION10
OVERDOSAGE16
ACTION AND CLINICAL PHARMACOLOGY17
STORAGE AND STABILITY21
DOSAGE FORMS, COMPOSITION AND PACKAGING21

PART II: SCIENTIFIC INFORMATION22
DETAILED PHARMACOLOGY23
TOXICOLOGY24
REFERENCES27

PART III: CONSUMER INFORMATION.....29

^NULTIVA[®]

(remifentanil hydrochloride)

PART I: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

Route of Administration	Dosage Form / Strength	Clinically Relevant Nonmedicinal Ingredients
i.v.	1 mg, 2 mg, 5 mg vials of remifentanil base as the hydrochloride salt	Glycine, hydrochloric acid <i>For a complete listing see Dosage Forms, Composition and Packaging section.</i>

INDICATIONS AND CLINICAL USE

^NULTIVA[®] (remifentanil hydrochloride) is indicated for i.v. administration as an analgesic agent for use during the induction and maintenance of general anesthesia for inpatient and outpatient procedures.

Due to insufficient safety and efficacy data, remifentanil is not recommended for use in spontaneous ventilation anesthesia, in monitored anesthesia care, for continuation as an analgesic in the immediate postoperative period, in neurosurgery, in cardiac surgery, or in paediatric anesthesia.

Geriatrics (> 65 years of age)

For details, see **DOSAGE AND ADMINISTRATION, Recommended Dose and Dosage Adjustment.**

Pediatrics

ULTIVA[®] is not indicated in children.

CONTRAINDICATIONS

Due to the presence of glycine in the formulation, ULTIVA® (remifentanyl hydrochloride) is contraindicated for epidural or intrathecal administration.

Remifentanyl is also contraindicated in patients with known hypersensitivity to the drug or any component of its formulation/preparation or to other fentanyl analogs.

WARNINGS AND PRECAUTIONS

General

Remifentanyl is not recommended for use as the sole agent in general anesthesia because loss of consciousness cannot be assured and because of a high incidence of apnea, muscle rigidity and tachycardia.

Continuous infusions of remifentanyl should be administered only by an infusion device. **I.V. bolus administration should only be used in intubated patients during the maintenance of general anesthesia.** For induction of anesthesia in nonintubated patients, a single dose of remifentanyl, not exceeding 1 µg/kg, may be administered over 30 to 60 seconds.

Interruption of an infusion of remifentanyl will result in rapid offset of effect. Rapid clearance and lack of drug accumulation result in rapid dissipation of respiratory depressant and analgesic effects upon discontinuation of remifentanyl at recommended doses. However, delayed respiratory depression may occur in some patients up to 30 minutes after termination of remifentanyl infusions due to residual effects of concomitant anesthetics. Discontinuation of an infusion of remifentanyl should be preceded by the establishment of adequate postoperative analgesia (see WARNINGS AND PRECAUTIONS, DOSAGE AND ADMINISTRATION).

Injections of remifentanyl should be made into i.v. tubing at or close to the venous cannula. Upon discontinuation of remifentanyl, the i.v. tubing should be removed or cleared to prevent the inadvertent administration of remifentanyl at a later point in time. **Failure to adequately clear the i.v. tubing to remove residual remifentanyl has been associated with the appearance of respiratory depression, apnea and muscle rigidity upon the administration of additional fluids or medications through the same i.v. tubing.**

Use of remifentanyl is associated with apnea and respiratory depression. Remifentanyl should be administered only in a setting fully equipped for the monitoring and support of respiratory and cardiovascular function. Resuscitative and intubation equipment, oxygen and an opioid antagonist must be readily available.

Remifentanyl should be administered only by persons specifically trained in the use of anesthetic drugs and the recognition and management of the expected adverse effects of

potent opioids, including respiratory and cardiac resuscitation of patients in the age-group being treated. Such training must include the establishment and maintenance of a patent airway and assisted ventilation.

Skeletal muscle rigidity can be caused by remifentanil and is related to the dose and speed of administration. Remifentanil may cause chest wall rigidity (inability to ventilate) after single doses $> 1 \mu\text{g}/\text{kg}$ administered over 30 to 60 seconds, or after infusion rates $> 0.1 \mu\text{g}/\text{kg}/\text{min}$. Single doses $< 1 \mu\text{g}/\text{kg}$ may cause chest wall rigidity when given concurrently with a continuous infusion of remifentanil.

Muscle rigidity induced by remifentanil should be managed in the context of the patient's clinical condition. Muscle rigidity occurring during the induction of anesthesia should be treated by the administration of a neuromuscular blocking agent and the concurrent induction medications.

Remifentanil should not be administered into the same i.v. tubing with blood/serum/plasma due to potential inactivation by nonspecific esterases in blood products.

Vital signs and oxygenation must be continually monitored during the administration of remifentanil.

Intraoperative awareness has been reported in patients under 55 years of age when remifentanil has been administered with propofol infusion rates of $\leq 75 \mu\text{g}/\text{kg}/\text{min}$. Therefore, propofol rates $< 100 \mu\text{g}/\text{kg}/\text{min}$ are not recommended for use with remifentanil for total intravenous anesthesia in patients < 55 years of age.

Carcinogenesis and Mutagenesis

Remifentanil, with or without a rat liver enzyme fraction (S9), was not mutagenic in the 5 strains of *Salmonella typhimurium* tested by gene mutation assay (Ames test) and did not produce chromosome aberrations in the Chinese hamster ovary cells. Remifentanil was also negative in the in vivo micronucleus test and the liver unscheduled DNA synthesis assay.

Remifentanil was found to be genotoxic in mammalian cells in vitro in the mouse lymphoma assay. Remifentanil concentrations over 4000 times greater than those seen with clinical use (50 ng/mL) were mutagenic only in the presence of metabolic activation.

Cardiovascular

Hypotension has been reported with remifentanil and is responsive to decreases in the administration of remifentanil or to i.v. fluids or catecholamine (ephedrine, epinephrine, norepinephrine, etc.) administration.

Dependence/Tolerance

As with other opioids, remifentanil can produce drug dependence of the morphine type and therefore has the potential of being abused.

Hepatic/Biliary/Pancreatic

Remifentanil pharmacokinetic/pharmacodynamic profile is not changed in patients with severe hepatic impairment. However, these patients may be slightly more sensitive to respiratory depressant effects of remifentanil. Therefore these patients should be closely monitored and the dose of remifentanil titrated to individual patient need.

Peri-Operative Considerations

Use in Cardiovascular Surgery

Clinical experience with remifentanil in patients undergoing cardiac surgery is limited to coronary artery bypass graft procedures (CABG). There are insufficient data to make a dosage recommendation.

Use in Neurosurgery

Due to the limited number of patients studied, there are insufficient data to make dosage recommendations.

Renal

The pharmacodynamic/pharmacokinetic profile of remifentanil is not changed in patients with end stage renal disease (creatinine clearance < 10 mL/min). No dosage adjustment is necessary in this patient population.

In anephric patients, the half-life of the carboxylic acid metabolite increases from 90 minutes to approximately 30 hours. The metabolite is removed by haemodialysis with a dialysis extraction ratio of approximately 30%.

Respiratory

Within 5 to 10 minutes after the discontinuation of ULTIVA[®] (remifentanil hydrochloride), no residual analgesic activity will be present. However, respiratory depression may occur in some patients up to 30 minutes after termination of infusion due to residual effects of concomitant anesthetics. Standard monitoring should be maintained in the postoperative period to ensure adequate recovery without stimulation. For patients undergoing surgical procedures where postoperative pain is generally anticipated, other analgesics should be administered prior to the discontinuation of remifentanil.

Bradycardia has been reported with remifentanyl and is responsive to ephedrine or anticholinergic drugs, such as atropine and glycopyrrolate.

Special Populations

Use During Pregnancy, Labour and Delivery, and Lactation

There are insufficient clinical data to support safety, and therefore, remifentanyl is not recommended for use in these populations.

Pediatrics (< 12 years of age):

Due to the limited number of patients studied, there are insufficient data to make dosage recommendations in the pediatric population.

Geriatrics (> 65 years of age):

The clearance of remifentanyl is reduced (approximately 25%) in the elderly (> 65 years of age) compared to young adults (average 25 years of age). However, remifentanyl blood concentrations fall as rapidly after termination of administration in the elderly as in young adults. The pharmacodynamic activity of remifentanyl (as measured by the EC₅₀ for development of delta waves on the electroencephalogram [EEG]) increases with increasing age. The EC₅₀ of remifentanyl for this measure was 50% less in patients over 65 years of age when compared to healthy volunteers (25 years of age); therefore, the recommended starting dose of remifentanyl should be decreased by 50% in elderly patients and then titrated to individual patient need (see **DOSAGE AND ADMINISTRATION**).

Morbidly Obese Patients

As for all potent opioids, caution is required when used in morbidly obese patients because of alterations in cardiovascular and respiratory physiology (see **DOSAGE AND ADMINISTRATION**).

ASA III/IV Patients

Limited data is available from 65 ASA III and 1 ASA IV patients. As the hemodynamic effects of potent opioids can be expected to be more pronounced in ASA III/IV patients, caution should be exercised in the administration of remifentanyl in this population. Initial dosage reduction and subsequent titration to effect is therefore recommended.

ADVERSE REACTIONS

Adverse Drug Reaction Overview

ULTIVA[®] (remifentanyl hydrochloride) produces adverse events that are characteristic of μ -opioids, such as respiratory depression, bradycardia, hypotension, and skeletal muscle rigidity. These adverse events dissipate within minutes of discontinuing or decreasing the infusion rate of remifentanyl (see **ACTION AND CLINICAL PHARMACOLOGY, WARNINGS AND PRECAUTIONS** on the management of these events).

Clinical Trial Adverse Drug Reactions

Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.

Adverse event information is derived from controlled clinical trials that were conducted in a variety of surgical procedures of varying duration, using a variety of premedications and other anesthetics, and in patient populations with diverse characteristics including underlying disease.

Approximately 2,492 patients were exposed to remifentanyl in controlled clinical trials. The frequencies of adverse events during general anesthesia with the recommended doses of ULTIVA[®] are given in **Table 1**.

In the elderly population (> 65 years), the incidence of hypotension is higher, whereas the incidence of nausea and vomiting is lower (see **WARNINGS AND PRECAUTIONS**).

Data from cardiac risk analysis in non-cardiac general anesthesia studies indicate the incidence of hypotension in patients with cardiac risk factors (i.e., > 65 years of age, concomitant use of cardiac medication) is higher with remifentanyl than comparator drugs (27% vs. 12%, respectively).

Table 1 Adverse Events 1% of Patients in General Anesthesia Studies at the Recommended Doses of Remifentanil*				
Adverse Event	Induction/Maintenance		After Discontinuation	
	Remifentanil (n = 921)	Alfentanil/Fentanyl (n = 466)	Remifentanil (n = 929)	Alfentanil/Fentanyl (n = 466)
Nausea	8 (<1%)	0	339 (36%)	202 (43%)
Hypotension	178 (19%)	30 (6%)	16 (2%)	9 (2%)
Vomiting	4 (<1%)	1 (<1%)	150 (16%)	91 (20%)
Muscle rigidity	98 (11%)**	37 (8%)	2 (<1%)	1 (<1%)
Bradycardia	62 (7%)	24 (5%)	11 (1%)	6 (1%)
Shivering	3 (<1%)	0	49 (5%)	10 (2%)
Fever	1 (<1%)	0	44 (5%)	9 (2%)
Dizziness	0	0	27 (3%)	9 (2%)
Visual disturbance	0	0	24 (3%)	14 (3%)
Headache	0	0	21 (2%)	8 (2%)
Respiratory depression	1 (<1%)	0	17 (2%)	20 (4%)
Apnea	0	1 (<1%)	2 (<1%)	1 (<1%)
Pruritis	2 (<1%)	0	22 (2%)	7 (2%)
Tachycardia	6 (<1%)	7 (2%)	10 (1%)	8 (2%)
Postoperative pain	0	0	4 (<1%)	5 (1%)
Hypertension	10 (1%)	7 (2%)	12 (1%)	8 (2%)
Agitation	2 (<1%)	0	6 (<1%)	1 (<1%)
Hypoxia	0	0	10 (1%)	7 (2%)

* Not all doses of remifentanil were equipotent to the comparator opioid. Administration of remifentanil in excess of the recommended dose (i.e., doses >1 and up to 20 µg/kg) resulted in a higher incidence of some adverse events: muscle rigidity (37%), bradycardia (12%), hypertension (4%), and tachycardia (4%).

** Included in the muscle rigidity incidence is chest wall rigidity (5%). The overall muscle rigidity incidence is reduced to <1% when remifentanil is administered concurrently with or after a hypnotic induction agent.

Less Common Clinical Trial Adverse Drug Reactions (<1%)

Other adverse events reported less frequently (<1%) include constipation and sedation.

Post-Market Adverse Drug Reactions

Very rarely, allergic reactions including anaphylaxis have been reported in patients receiving ULTIVA® in conjunction with one or more anesthetic agents.

DRUG INTERACTIONS

Overview

Drug-Drug Interactions

Remifentanil clearance is not altered by concomitant administration of thiopental, isoflurane, propofol or temazepam during anesthesia. *In vitro* studies with atracurium, mivacurium, esmolol, echothiophate, neostigmine, physostigmine and midazolam revealed no inhibition of remifentanil hydrolysis in whole human blood by these drugs. In animals the duration of muscle paralysis from succinylcholine is not prolonged by remifentanil.

Remifentanil is synergistic with other anesthetics and doses of thiopental, propofol, isoflurane and midazolam have been reduced by up to 75% with the coadministration of remifentanil. If doses of concomitantly administered CNS depressant drugs are not reduced, patients may experience an increased incidence of adverse effects associated with these agents.

DOSAGE AND ADMINISTRATION

Dosing Considerations

Due to insufficient safety and efficacy data, ULTIVA[®] (remifentanil hydrochloride) is not recommended for use in spontaneous ventilation anesthesia, in monitored anesthesia care, for continuation as an analgesic in the immediate postoperative period, in neurosurgery, in cardiac surgery, or in pediatric anesthesia.

Remifentanil is not recommended as the sole agent in general anesthesia because loss of consciousness cannot be assured and because of a high incidence of apnea, muscle rigidity, and tachycardia.

Recommended Dose and Dosage Adjustment

Remifentanil is synergistic with other anesthetics and doses of thiopental, propofol, isoflurane and midazolam have been reduced by up to 75% with the coadministration of remifentanil. At the recommended doses shown in **Table 2**, remifentanil significantly reduces the amount of hypnotic agent required to maintain anesthesia. Therefore isoflurane and propofol should be administered as recommended below to avoid excessive depth of anesthesia.

Intraoperative awareness has been reported in patients under 55 years of age when remifentanil has been administered with propofol infusion rates of ≤ 75 $\mu\text{g}/\text{kg}/\text{min}$. Therefore, propofol rates <100 $\mu\text{g}/\text{kg}/\text{min}$ are not recommended for use with remifentanil for total intravenous anesthesia in patients < 55 years of age.

I.V. bolus administration should only be used in intubated patients during the maintenance of general anesthesia. For induction of anesthesia in nonintubated patients, a single dose of remifentanyl, not exceeding 1 µg/kg, may be administered over 30 to 60 seconds.

Reconstituted solutions of remifentanyl should be diluted prior to administration (see **DOSAGE AND ADMINISTRATION, Reconstitution, Parenteral Products**).

The administration of remifentanyl must be individualized based on the patient's response. **Table 2** summarizes the recommended doses in adult patients, predominately ASA physical status I, II, or III.

Phase	Continuous i.v. Infusion of ULTIVA® (µg/kg/min)	Infusion Dose Range of ULTIVA® (µg/kg/min)	Supplemental i.v. Bolus Dose of ULTIVA® (µg/kg)
Induction of Anesthesia (through intubation)	0.5 - 1†		
Maintenance of anesthesia with:			
Nitrous oxide (66%)	0.4	0.1-2	0.5-1
Isoflurane (starting dose 0.5 MAC)	0.25	0.05-2	0.5-1
Propofol (starting dose 100 µg/kg/min)	0.25	0.05-2	0.5-1

† An initial dose of 1 µg/kg may be administered over 30 to 60 seconds.

During Induction of Anesthesia

Remifentanyl should be administered at an infusion rate of 0.5 to 1 µg/kg/min with a hypnotic or volatile agent for the induction of anesthesia. If endotracheal intubation is to occur less than 8 minutes after the start of the infusion of remifentanyl, then an initial dose of 1 µg/kg may be administered over 30 to 60 seconds.

During Maintenance of Anesthesia

After endotracheal intubation, the infusion rate of remifentanyl should be decreased in accordance with the dosing guidelines in **Table 2**. Due to the fast onset and short duration of action of remifentanyl, the rate of administration during anesthesia can be titrated upward in 25% to 100% increments or downward in 25% to 50% decrements every 2 to 5 minutes to attain the desired level of µ-opioid effect. In response to light anesthesia or transient episodes of intense surgical stress, supplemental bolus doses of 0.5 to 1 µg/kg may be administered every 2 to 5 minutes. At infusion rates >1 µg/kg/min, increases in the concomitant anesthetic agents should be considered to increase the depth of anesthesia.

Guidelines for Discontinuation

Upon discontinuation of remifentanyl, the i.v. tubing should be cleared to prevent the inadvertent administration of remifentanyl at a later time. Due to the rapid offset of action of remifentanyl, no residual analgesic activity will be present within 5 to 10 minutes after discontinuation. However respiratory depression may occur in some patients up to 30 minutes after termination of infusion due to residual effects of concomitant anesthetics. Standard monitoring should be maintained in the postoperative period to ensure adequate recovery without stimulation. For those patients undergoing surgical procedures where postoperative pain is generally anticipated, alternative analgesics should be administered prior to discontinuation of remifentanyl. Sufficient time must be allowed to reach the maximum effect of the longer acting analgesic. The choice of analgesic should be appropriate for the patient's surgical procedure and the level of follow-up care.

Use in Elderly Patients

Due to the increased sensitivity to the pharmacological effects of remifentanyl in this population (> 65 years), the starting doses of remifentanyl should be decreased by 50% and then be titrated to individual patient need.

Use in Obese Patients

The starting doses of remifentanyl should be based on ideal body weight in obese patients as the clearance and volume of distribution of remifentanyl are better correlated with ideal body weight than actual body weight in this population.

Preanesthetic Medication

The need for premedication and the choice of anesthetic agents must be individualized. In clinical studies, patients who received remifentanyl frequently received a benzodiazepine premedication.

Individualization of Infusion Rates

Infusion rates of ULTIVA[®] can be individualized for each patient using **Table 3**.

Drug Delivery Rate (µg/kg/min)	Infusion Delivery Rate (mL/kg/h)		
	25 µg/mL	50 µg/mL	250 µg/mL
0.05	0.12	0.06	0.012
0.075	0.18	0.09	0.018
0.1	0.24	0.12	0.024
0.15	0.36	0.18	0.036
0.2	0.48	0.24	0.048
0.25	0.6	0.3	0.06

Table 3			
Infusion Rates of ULTIVA® (mL/kg/h)			
Drug Delivery Rate (µg/kg/min)	Infusion Delivery Rate (mL/kg/h)		
	25 µg/mL	50 µg/mL	250 µg/mL
0.5	1.2	0.6	0.12
0.75	1.8	0.9	0.18
1.0	2.4	1.2	0.24
1.25	3.0	1.5	0.3
1.5	3.6	1.8	0.36
1.75	4.2	2.1	0.42
2.0	4.8	2.4	0.48

Table 4 is a guideline for milliliter-per-hour delivery for a solution of 25 µg/mL with an infusion device.

Table 4								
Infusion Rates of ULTIVA® (mL/h) for a 25-µg/mL Solution								
Infusion Rate (µg/kg/min)	Patient Weight (kg)							
	30	40	50	60	70	80	90	100
0.05	3.6	4.8	6.0	7.2	8.4	9.6	10.8	12.0
0.075	5.4	7.2	9.0	10.8	12.6	14.4	16.2	18.0
0.1	7.2	9.6	12.0	14.4	16.8	19.2	21.6	24.0
0.15	10.8	14.4	18.0	21.6	25.2	28.8	32.4	36.0
0.2	14.4	19.2	24.0	28.8	33.6	38.4	43.2	48.0

Table 5 is a guideline for milliliter-per-hour delivery for a solution of 50 µg/mL with an infusion device.

Table 5								
Infusion Rates of ULTIVA® (mL/h) for a 50-µg/mL Solution								
Infusion Rate (µg/kg/min)	Patient Weight (kg)							
	30	40	50	60	70	80	90	100
0.05	1.8	2.4	3.0	3.6	4.2	4.8	5.4	6.0
0.075	2.7	3.6	4.5	5.4	6.3	7.2	8.1	9.0
0.1	3.6	4.8	6.0	7.2	8.4	9.6	10.8	12.0
0.15	5.4	7.2	9.0	10.8	12.6	14.4	16.2	18.0
0.2	7.2	9.6	12.0	14.4	16.8	19.2	21.6	24.0
0.25	9.0	12.0	15.0	18.0	21.0	24.0	27.0	30.0
0.5	18.0	24.0	30.0	36.0	42.0	48.0	54.0	60.0
0.75	27.0	36.0	45.0	54.0	63.0	72.0	81.0	90.0
1.0	36.0	48.0	60.0	72.0	84.0	96.0	108.0	120.0
1.25	45.0	60.0	75.0	90.0	105.0	120.0	135.0	150.0
1.5	54.0	72.0	90.0	108.0	126.0	144.0	162.0	180.0
1.75	63.0	84.0	105.0	126.0	147.0	168.0	189.0	210.0
2.0	72.0	96.0	120.0	144.0	168.0	192.0	216.0	240.0

Table 6 is a guideline for milliliter-per-hour delivery for a solution of 250 µg/mL with an infusion device.

Table 6								
Infusion Rates of ULTIVA® (mL/h) for a 250-µg/mL Solution								
Infusion Rate (µg/kg/min)	Patient Weight (kg)							
	30	40	50	60	70	80	90	100
0.1	0.72	0.96	1.20	1.44	1.68	1.92	2.16	2.40
0.15	1.08	1.44	1.80	2.16	2.52	2.88	3.24	3.60
0.2	1.44	1.92	2.40	2.88	3.36	3.84	4.32	4.80
0.25	1.80	2.40	3.00	3.60	4.20	4.80	5.40	6.00
0.5	3.60	4.80	6.00	7.20	8.40	9.60	10.80	12.00
0.75	5.40	7.20	9.00	10.80	12.60	14.40	16.20	18.00
1.0	7.20	9.60	12.00	14.40	16.80	19.20	21.60	24.00
1.25	9.00	12.00	15.00	18.00	21.00	24.00	27.00	30.00
1.5	10.80	14.40	18.00	21.60	25.20	28.80	32.40	36.00
1.75	12.60	16.80	21.00	25.20	29.40	33.60	37.80	42.00
2.0	14.40	19.20	24.00	28.80	33.60	38.40	43.20	48.00

Missed Dose

Not applicable.

Administration

Remifentanyl should be administered only in a setting fully equipped for the monitoring and support of respiratory and cardiovascular function. Resuscitative and intubation equipment, oxygen and an opioid antagonist must be readily available.

Remifentanyl should only be administered by persons specifically trained in the use of anesthetic drugs and the recognition and management of the expected adverse effects of potent opioids, including respiratory and cardiac resuscitation of patients in the age-group being treated. Such training must include the establishment and maintenance of a patent airway and assisted ventilation.

Remifentanyl is for i.v. use only and must not be administered by epidural or intrathecal injection. Continuous infusions of remifentanyl should be administered only by an infusion device. The injection site should be close to the venous cannula and all i.v. tubing should be cleared at the time of discontinuation of infusion.

Reconstitution:

Parenteral Products:

Preparation for Administration

To reconstitute solution, add 1 mL of diluent per mg of remifentanil. Shake well to dissolve. When reconstituted as directed, the solution contains approximately 1 mg of remifentanil activity per 1 mL. ULTIVA® should be reconstituted and diluted to a recommended final concentration of 25, 50, or 250 µg/mL prior to administration as indicated in **Table 7** and **Table 8** below. **ULTIVA® should not be administered without dilution.** ULTIVA® does not contain any antimicrobial preservatives and thus care must be taken to assure the sterility of prepared solutions.

ULTIVA® can be reconstituted and diluted to concentrations of 20 to 250 µg/mL in any of the following i.v. fluids:

- Sterile Water for Injection, USP
- 5% Dextrose Injection, USP
- 5% Dextrose and 0.9% Sodium Chloride Injection, USP
- 0.9% Sodium Chloride Injection, USP
- 0.45% Sodium Chloride Injection, USP
- Lactated Ringer's and 5% Dextrose Injection, USP
- Lactated Ringer's Injection, USP

ULTIVA® has been shown to be compatible with these i.v. fluids when coadministered into a running i.v. administration set.

Table 7 Reconstitution of ULTIVA®			
Vial Size (mg of remifentanil base)	Volume of Diluent to be Added to Vial	Approximate* Available Volume	Nominal Concentration
1 mg	1 mL	1 mL	1 mg/mL
2 mg	2 mL	2 mL	1 mg/mL
5 mg	5 mL	5 mL	1 mg/mL

* Densities for water and reconstituted ULTIVA are not significantly different

Table 8 Dilution of ULTIVA®			
Final Concentration	Amount of remifentanil in Each Vial	Volume to be Added to Dilute*	Final Volume after Dilution
25 µg/mL	1 mg	39 mL	40 mL
	2 mg	78 mL	80 mL
	5 mg	195 mL	200 mL
50 µg/mL	1 mg	19 mL	20 mL

Final Concentration	Amount of remifentanil in Each Vial	Volume to be Added to Dilute*	Final Volume after Dilution
	2 mg	38 mL	40 mL
	5 mg	95 mL	100 mL
250 µg/mL	5 mg	15 mL	20 mL
* note amounts indicated are those to be added after ULTIVA has been reconstituted to a 1 mg/mL solution as indicated in Table 7 above.			

Compatibility With Other Therapeutic Agents

ULTIVA® has been shown to be compatible with Propofol Injection when coadministered into a running i.v. administration set. The compatibility of ULTIVA® with other therapeutic agents has not been evaluated.

Incompatibilities

Nonspecific esterases in blood products may lead to the hydrolysis of remifentanil to its carboxylic acid metabolite. Therefore, administration of ULTIVA® into the same i.v. tubing with blood/serum/plasma is not recommended.

Note: Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Product should be a clear, colorless liquid after reconstitution and free of visible particulate matter.

OVERDOSAGE

As with all potent opioid analgesics, overdose would be manifested by an extension of the pharmacological actions of ULTIVA® (remifentanil hydrochloride). Expected signs and symptoms of overdose include: apnea, chest-wall rigidity, seizures, hypoxemia, hypotension, and bradycardia.

In case of overdose or suspected overdose, discontinue administration of remifentanil, maintain a patent airway, initiate assisted or controlled ventilation with oxygen, and maintain adequate cardiovascular function. If depressed respiration is associated with muscle rigidity, a neuromuscular blocking agent or a µ-opioid antagonist may be required to facilitate assisted or controlled respiration. Intravenous fluids and vasopressors for the treatment of hypotension and other supportive measures may be employed. Glycopyrrolate or atropine may be useful for the treatment of bradycardia and/or hypotension.

Intravenous administration of an opioid antagonist such as naloxone may be employed as a specific antidote to manage severe respiratory depression or muscle rigidity. Respiratory depression following overdose with remifentanil is not expected to last longer than the opioid antagonist, naloxone. Reversal of the opioid effects may lead to acute pain and sympathetic hyperactivity.

ACTION AND CLINICAL PHARMACOLOGY

Mechanism of Action

ULTIVA® (remifentanyl hydrochloride) is a μ -opioid agonist with rapid onset and peak effect, and ultra-short duration of action. The μ -opioid activity of remifentanyl is antagonized by opioid antagonists such as naloxone.

The analgesic effects of remifentanyl are rapid in onset and offset. Its effects and side effects are dose dependent and similar to other μ -opioids. Remifentanyl in humans has a rapid blood-brain equilibration half-time of 1 ± 1 minutes (mean \pm SD) and a rapid onset of action. The pharmacodynamic effects of remifentanyl closely follow the measured blood concentrations, allowing direct correlation between dose, blood levels, and response. Blood concentration decreases 50% in 3 to 6 minutes after a 1-minute infusion or after prolonged continuous infusion due to rapid distribution and elimination processes and is independent of duration of drug administration. Recovery from the effects of remifentanyl occurs rapidly (within 5 to 10 minutes). New steady-state concentrations occur within 5 to 10 minutes after changes in infusion rate. When used as a component of an anesthetic technique, remifentanyl can be rapidly titrated to the desired depth of anesthesia/analgesia (e.g., as required by varying levels of intraoperative stress) by changing the continuous infusion rate or by administering an i.v. bolus injection.

Pharmacodynamics

Haemodynamics

In premedicated patients undergoing anesthesia, 1-minute infusions of $< 2 \mu\text{g}/\text{kg}$ of remifentanyl caused dose-dependent hypotension and bradycardia. While additional doses $> 2 \mu\text{g}/\text{kg}$ (up to $30 \mu\text{g}/\text{kg}$) do not produce any further decreases in heart rate or blood pressure, the duration of the hemodynamic change is increased in proportion to the blood concentrations achieved. Peak hemodynamic effects occur within 3 to 5 minutes of a single dose of remifentanyl or an infusion rate increase. Glycopyrrolate, atropine, and vagolytic neuromuscular blocking agents attenuate the hemodynamic effects associated with remifentanyl. When appropriate, bradycardia and hypotension can be reversed by reduction of the rate of infusion of remifentanyl, or the dose of concurrent anesthetics, or by the administration of fluids or vasopressors.

Respiration

Remifentanyl depresses respiration in a dose-related fashion. Unlike other fentanyl analogs, the duration of action of remifentanyl at a given dose does not increase with increasing duration of administration, due to lack of drug accumulation. When remifentanyl and alfentanil were dosed to equal levels of respiratory depression, recovery of respiratory drive after 3-hour infusions was more rapid and less variable with remifentanyl (see **Figure 1**).




Figure 1: Recovery of Respiratory Drive After Equipotent* Doses of Remifentanyl and Alfentanil Using CO₂-Stimulated Minute Ventilation in Volunteers (±1.5 SEM)

*Equipotent refers to level of respiratory depression.

Spontaneous respiration occurs at blood concentrations of 4 to 5 ng/mL in the absence of other anesthetic agents; for example, after discontinuation of a 0.25-µg/kg/min infusion of remifentanyl, these blood concentrations would be reached in 2 to 4 minutes. In patients undergoing general anesthesia, the rate of respiratory recovery depends upon the concurrent anesthetic; N₂O < propofol < isoflurane.

Muscle Rigidity

Skeletal muscle rigidity can be caused by remifentanyl and is related to the dose and speed of administration. Remifentanyl may cause chest wall rigidity (inability to ventilate) after single doses of > 1 µg/kg administered over 30 to 60 seconds or infusion rates > 0.1 µg/kg/min; peripheral muscle rigidity may occur at lower doses. Administration of doses < 1 µg/kg may cause chest wall rigidity when given concurrently with a continuous infusion of remifentanyl. Prior or concurrent administration of a hypnotic (propofol or thiopental) or a neuromuscular blocking agent may attenuate the development of muscle rigidity. Excessive muscle rigidity can be treated by decreasing the rate or discontinuing the infusion of remifentanyl or by administering a neuromuscular blocking agent.

Histamine Release

Assays of histamine in patients and normal volunteers have shown no elevation in plasma histamine levels after administration of remifentanyl in doses up to 30 µg/kg over 60 seconds.

Anesthesia

Remifentanil is synergistic with the activity of hypnotics (propofol and thiopental), inhaled anesthetics, and benzodiazepines (see **WARNINGS AND PRECAUTIONS**, and **DOSAGE AND ADMINISTRATION**).

Gender

No differences have been shown in the pharmacodynamic activity (as measured by the EEG) of remifentanil between men and women.

Pharmacokinetics

Absorption

After i.v. doses administered over 60 seconds, the pharmacokinetics of remifentanil fit a three-compartment model with a rapid distribution half-life of 1 minute, a slower distribution half-life of 6 minutes, and a terminal elimination half-life of 10 to 20 minutes. Since the terminal elimination component contributes less than 10% of the overall area under the concentration versus time curve (AUC), the effective biological half-life of remifentanil is 3 to 10 minutes. This is similar to the 3- to 10-minute half-life measured after termination of prolonged infusions (up to 4 hours; see **Figure 2**) and correlates with recovery times observed in the clinical setting after infusions up to 12 hours. Concentrations of remifentanil are proportional to the dose administered throughout the recommended dose range. The pharmacokinetics of remifentanil are unaffected by the presence of renal or hepatic impairment.

Distribution

The initial volume of distribution (V_d) of remifentanil is approximately 100 mL/kg and represents distribution throughout the blood and rapidly perfused tissues. Remifentanil subsequently distributes into peripheral tissues with a steady-state volume of distribution of approximately 350 mL/kg. These two distribution volumes generally correlate with total body weight (except in severely obese patients when they correlate better with ideal body weight [IBW]). Remifentanil is approximately 70% bound to plasma proteins of which two-thirds is binding to alpha-1-acid-glycoprotein.

Metabolism

Remifentanil is an esterase-metabolized opioid. A labile ester linkage renders this compound susceptible to hydrolysis by nonspecific esterases in blood and tissues. This hydrolysis results in production of the carboxylic acid metabolite (3-[4-methoxycarbonyl-4-[(1-oxopropyl)phenylamino]-1-piperidine]propanoic acid), and represents the principal metabolic pathway for remifentanil (> 95%). The carboxylic acid metabolite is essentially inactive (1/4 600 as potent as remifentanil in dogs) and is excreted by the kidneys with an elimination

half-life of approximately 90 minutes. Remifentanyl is not metabolized by plasma cholinesterase (pseudocholinesterase) and is not appreciably metabolized by the liver or lung.

Excretion

The clearance of remifentanyl in young, healthy adults is approximately 40 mL/min/kg. Clearance generally correlates with total body weight (except in severely obese patients when it correlates better with ideal body weight). The high clearance of remifentanyl combined with a relatively small volume of distribution produces a short elimination half-life of approximately 3 to 10 minutes (see **Figure 2**). This value is consistent with the time taken for blood or effect site concentrations to fall by 50% (context-sensitive half-times), which is approximately 3 to 6 minutes. Unlike other fentanyl analogs, the duration of action does not increase with prolonged administration.




Figure 2 Mean Concentration (sd) versus Time

Titration to Effect

The rapid elimination of remifentanyl permits the titration of infusion rate without concern for prolonged duration. In general, every 0.1- μ g/kg/min change in the i.v. infusion rate will lead to a corresponding 2.5-ng/mL change in blood remifentanyl concentration within 5 to 10 minutes. In intubated patients only, a more rapid increase (within 3 to 5 minutes) to a new steady state can be achieved with a 1.0- μ g/kg bolus dose in conjunction with an infusion rate increase.

STORAGE AND STABILITY

ULTIVA[®] for Injection should be stored between 2 to 25°C. Reconstituted and diluted solutions of ULTIVA[®] (20 to 250 µg/mL) are stable for 24 hours at room temperature for all recommended i.v. fluids except those containing Lactated Ringer's Solution (stable for 4 hours).

DOSAGE FORMS, COMPOSITION AND PACKAGING

ULTIVA[®] (remifentanil hydrochloride) for Injection is available as:

- 1 mg remifentanil base lyophilized powder in 3 mL vials (cartons of 5)
- 2 mg remifentanil base lyophilized powder in 5 mL vials (cartons of 5)
- 5 mg remifentanil base lyophilized powder in 10 mL vials (cartons of 5).

PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance


Proper name: remifentanil hydrochloride

Chemical name: 1-piperidinepropanoic acid, 4-(methoxycarbonyl)-4-[(1-oxopropyl)phenylamino]-, methyl ester, monohydrochloride

Molecular formula: $C_{20}H_{28}N_2O_5 \cdot HCl$

Molecular mass: 412.9

Structural formula:



Physicochemical properties:

Physical Characteristics: White to off-white solid

pH and pKa: pH (1% solution of drug substance) is approximately 5
pH (reconstituted i.v. solution) = 2.5-3.5
pKa = 7.07

Melting Point: approximately 205°C

Solubility: 150 mg/mL in unbuffered water, and 5% Dextrose Injection USP
120 mg/mL in 0.9% Sodium Chloride Injection USP

Composition: ULTIVA® (remifentanil hydrochloride) for injection contains 1 mg, 2 mg or 5 mg of remifentanil base (as the

hydrochloride salt) per vial. Non-medicinal ingredients include Glycine 15 mg and Hydrochloric Acid (adjust pH).

DETAILED PHARMACOLOGY

Animal Pharmacology

Pharmacodynamics

The antinociceptive properties of remifentanyl were determined by rodent tail withdrawal in response to noxious radiant heat and by canine paw withdrawal in response to a noxious pinch. The potency of remifentanyl seen was similar to that of alfentanil, fentanyl and sufentanil. Reversal of antinociception by naloxone confirmed that this response was opioid receptor-mediated.

Duration of antinociceptive response following intravenously administered remifentanyl was dose-related and was much shorter than that of alfentanil, fentanyl, or sufentanil. Remifentanyl did not accumulate with repeated or prolonged administration.

Receptor binding studies confirmed remifentanyl was selective for the μ -opioid receptor. EC_{50} values for remifentanyl at μ -, δ -, κ -opioid receptors were 2.6 nM, 66 nM, and 6.1 μ M, respectively. In isolated tissues, remifentanyl was a potent μ -opioid agonist, with its actions reversed by the μ -opioid antagonist, naltrexone, but not by the δ - and κ -opioid antagonists, ICI-174864 and nor-binaltorphimine, respectively. Therefore, although remifentanyl has some affinity for δ - and κ -opioid receptors in binding assays, it lacks the intrinsic efficacy to produce significant activation at these receptors.

Secondary effects produced by remifentanyl are characteristic for μ -opioid agonists (consisting of dose-related bradycardia and hypotension) but are consistently shorter in duration than for other opioids. These hemodynamic effects may lessen the cardiovascular risk, and may ameliorate increased heart rate and blood pressure seen during the intraoperative stress response to surgery and anesthesia.

Pharmacokinetics

The propanoic acid methyl ester moiety of remifentanyl is rapidly hydrolyzed by esterases in the blood and tissues to yield the carboxylic acid of remifentanyl (and also the major metabolite). After infusion of remifentanyl, the pharmacokinetics in dogs are linear between 0.4 μ g/kg/min and the highest rate tested 40 μ g/kg/min. The pharmacokinetics of remifentanyl in beagle dogs and the metabolism and excretion of remifentanyl in mice, rats, rabbits and dogs are similar to those in humans. Remifentanyl does not accumulate upon repeated administration in any of the animal species studied.

Elimination is primarily through urine in all toxicological species as well as humans. The only other identified metabolite (other than the carboxylic acid of remifentanyl) found in urine or feces of mice, rats or dogs was the product of N-dealkylation on the piperidine ring. It accounted for less than 2% of the dose in all animals species.

Approximately 16-18% of the total systemic clearance of remifentanyl could be accounted for in liver, kidney, blood, muscle, brain and lung. Of these, muscle contributed most to the clearance (5-9%). Liver or kidney contributed only 0-3%. This suggests that hepatic or renal insufficiency in humans should not impact greatly on remifentanyl clearance.

Remifentanyl was approximately 70% bound to human plasma proteins, mostly to α -1-acid glycoprotein.

TOXICOLOGY

Acute Toxicology

Maximum Non Lethal Doses observed in animals (and corresponding multiples of the clinical dose) seen in acute toxicology studies were:

Species/Sex	MNLD mg/kg	Clinical Multiple ^a
Male mice	84	42,000
Female mice	70	25,000
Male rat	5	2,500
Female rat	7.5	3,750
Male and female dogs	80	40,000

^a Based on the maximum recommended human bolus dose of 2 μ g /kg

In all studies, remifentanyl produced expected signs of μ -opioid intoxication when administered as large single bolus intravenous doses to non-ventilated mice, rats and dogs. In the rat and mouse studies, no macroscopic or microscopic changes could be attributed to administration of remifentanyl. Hypoxia-induced brain microhemorrhages were observed in dogs, but these were not present in dogs killed 14 days after dosing, suggesting reversibility of this effect.

Long-Term Toxicology

Subacute Toxicity Studies

Species	Route	Dose	Duration of Study	Results
Rat	Continuous i.v. Infusion	up to 5 μ g/kg/min	2 weeks	\downarrow food consumption and bodyweight gain, \downarrow pancreatic acinar cell zymogen granules, \uparrow serum glucose.

Species	Route	Dose	Duration of Study	Results
	Bolus i.v.	up to 2.5 mg/kg/day	4 weeks	↓ absolute and relative epididymus weight
Dog	Continuous i.v. Infusion	up to 0.25 µg/kg/min	2 weeks	↓ food consumption and bodyweight gain
	Bolus i.v.	up to 40 mg/kg/day*	4 weeks	brain microhemorrhages
	Bolus Intrathecal	100-1600 µg**	19 days	agitation, pain, ↑ in heart rate and blood pressure, hindlimb dysfunction
* Dosing was reduced to 1.0 mg/kg/day on day 5 due to severity of clinical signs				
** Initial dose which was doubled daily up to 1600 µg after which the maximum tolerated dose (800 µg) was administered daily for 14 days.				

The toxicological profile of remifentanil is consistent with that expected from a potent μ -opioid agonist. Clinical signs of opioid intoxication were observed in both rats and dogs. Respiratory depression led to death in some animals. The incidence of clonic convulsions increased with increasing days of dosing in both species in the 4 week bolus studies.

In the 4 week rat bolus study, slightly reduced absolute and relative epididymal weights were observed at 2.5 mg/kg/day and sloughed epithelial cells were noted in epididymal tubules at 0.25, 1.0 and 2.5 mg/kg/day. These observations are not predictive of effects in man, where clinical exposure is brief and at relatively low doses.

Continuous infusion of remifentanil to rats was associated with a reversible increase (up to 54%) in serum glucose. Microscopic findings were limited to a reversible decrease in pancreatic acinar cell zymogen granules in mid and high dose animals.

Microscopic brain hemorrhages were noted in the midbrain areas of dogs receiving 0.03 and 0.05 mg/kg (at least 15 times the maximum recommended human bolus dose of 2 µg/kg). These hemorrhages were reversible, and are thought to be due to hypoxia. Additional studies in ventilated dogs showed that adequate ventilation eliminated the occurrence of microhemorrhages, or reduced their incidence to below that seen in dogs treated with saline alone.

Single and repeat dose comparator studies in non-ventilated dogs with bolus intravenous injections of up to 1 mg/kg alfentanil, resulted in morphologically identical microscopic brain hemorrhages, confirming that this finding was not specific to remifentanil.

Intrathecal administration of remifentanil to dogs produced hindlimb dysfunction and increased agitation and pain. Bolus intrathecal doses of the glycine formulation (without remifentanil) resulted in clinical observations of agitation and pain, but no microscopic evidence of tissue damage. These effects are believed to be secondary to the glycine excipient. Because of the better buffering properties of blood, the more rapid dilution, and the low glycine concentration of the ULTIVA[®] formulation, this finding has no clinical relevance for intravenous administration of ULTIVA[®].

Reproduction and Teratology

There were no adverse effects on the mating performance of male and female rats, as well as on fertility of female rats. The male fertility index (number of pregnancies/number of rats that mated) was reduced, probably due to decreases in testes and epididymal weights and increased incidences of macroscopic lesions and microscopic changes in these organs. However, these changes were observed only after prolonged exposure to relatively high doses of remifentanil, and are not relevant to its clinical use.

In organogenesis studies in rats and rabbits, remifentanil was not considered to present a developmental hazard to fetuses. Maternal toxicity was considered responsible for the reduced fetal bodyweights in rats, as well as two abortions, increased incidences of resorption, and the increased fetal incidence of the skeletal variation of “greater than 12 full pair of ribs” in rabbits.

Placental and milk transfer studies showed that pups are exposed to remifentanil and/or its metabolites during growth and development.

REFERENCES

These references are intended to support only approved indications in the product monograph and not the non-approved indications even though they may be mentioned in some of the publications listed.

1. Amin HM, Sopchak AM, Esposito BF, Graham CL, Batenhorst RL, Camporesi EM. Naloxone reversal of depressed ventilatory response to hypoxia during continuous infusion of remifentanil. *Anesthesiology* 1993; 79(3A):A1203.
2. Derschwitz M, Rosow CE, Michalowski P, Connors PM, Hoke JF, Muir KT, Dienstag JL. Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease compared with normal subjects. *Anesthesiology* 1994; 81:A377.
3. Egan TD, Lemmens HJM, Fiset P, Hermann DJ, Muir KT, Stanski DR, Shafer SL. The pharmacokinetics of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteers. *Anesthesiology* 1993; 79(5):881-892.
4. Fragan RJ. Implications of the use of remifentanil on patient outcomes. *Eur J Anaesth* 1995; 12(10): 75-76.
5. Glass PSA. Pharmacology of remifentanil. *Eur J Anaesth* 1995; 12(10):73-74.
6. Hoke JF, Muir KT, Glass PSA, Shlugman D, Rosow CE, Derschwitz M, Michalowski P. Pharmacokinetics (PK) of remifentanil (R) and its metabolite (GR90291) in subjects with renal disease. *Clin Pharmacol Ther* 1995; 57(2): PI-55.
7. James MK. Remifentanil and anaesthesia for the future. *Exp Opin Invest Drugs* 1994; 3(4):331-340.
8. Kapila A, Lang E, Glass P, Sebel P, Shlugman D, Hill A, Wood M, Batenhorst R, Goodman D. MAC reduction of isoflurane by remifentanil. *Anesthesiology* 1994; 81(3A):A378.
9. Marton JP, Hardman HD, Kamiyama Y, Donn KH., Glass PSA. Analgesic efficacy of single escalating doses of GI87084B administered intravenously to healthy male volunteers. *Anesthesiology* 1991; 75: A378.
10. Minto CF, Schnider THW, Cohane CA, Gambus PH, Lemmens H, Shafer SL. The hemodynamic effects of remifentanil in volunteers over 70 years. *Anesthesiology* 1994; 81(3A):A11.
11. Monk TG, Batenhorst RL, Folger WH, Kirkham AJT, Lemon DJ, Martin KJ., Venker DC. A comparison of remifentanil and alfentanil during nitrous-narcotic anaesthesia. *Anesth Analg* 1994; 78:S293.

12. Robinson C, Castaher J. Remifentanil hydrochloride. *Drugs of the future* 1994; 19(12):1088-1092.
13. Sebel PS, Hoke JF, Westmoreland C, Hug CC, Muir KT, Szlam F. Histamine concentrations and hemodynamic responses after remifentanil. *Anesth Analg* 1995; 80:990-993.
14. Shlugman D, Dufore S, Dershwitz M, Michalowski P, Hoke J, Muir KT, Dosow C, Glass PSA. Respiratory effects of remifentanil in subjects with severe renal impairment compared to matched controls. *Anesthesiology* 1994; 81(3A): A1417.
15. Westmoreland CL, Hoke JF, Sebel PS, Hug CC, Muir KT. Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. *Anesthesiology* 1993; 79:893-903.
16. Patel SS, Spencer CM. Remifentanil. *Drugs* 1996, 52(3):417-427.

PART III: CONSUMER INFORMATION

^NULTIVA[®] (Remifentanil Hydrochloride)

This leaflet is part III of a three-part “Product Monograph” published when ^NULTIVA[®] was approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about ^NULTIVA[®]. Contact your doctor or pharmacist if you have any questions about the drug.

ABOUT THIS MEDICATION

What the medication is used for:

ULTIVA[®] is a pain medication used before and/ or during surgery.

What it does:

ULTIVA[®] reduces the pain during surgery.

When it should not be used:

ULTIVA[®] should not be used in patients who:

- are allergic to remifentanil
- are pregnant or nursing

What the medicinal ingredient is:

Remifentanil hydrochloride

What the nonmedicinal ingredients are:

Glycine, hydrochloric acid, water for injection.

WARNINGS AND PRECAUTIONS

BEFORE you undergo surgery, tell your doctor or pharmacist if:

- you are pregnant or nursing
- you are allergic to remifentanil

INTERACTIONS WITH THIS MEDICATION

Tell your doctor if you are taking :

- benzodiazepines (Valium, Versed)
- opioids (Morphine, Codeine)

They may interact with ULTIVA[®].

PROPER USE OF THIS MEDICATION

Usual dose:

The proper dose is determined by a doctor trained in the administration of analgesics and general anesthesia.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Common side effects include: respiratory depression, slow heartbeat, low blood pressure, and skeletal muscle rigidity. Your anesthetist knows how to manage them during surgery.

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM

You should immediately contact your physician or anesthesia professional if you have any of the following reactions after surgery.

- Nausea
- Low blood pressure
- Vomiting
- Muscle tightness
- Slow heartbeat
- Shivering
- Fever
- Dizziness
- Visual disturbance
- Headache
- Respiratory depression
- Transient cessation of respiration
- Itch
- Rapid heartbeat
- Postoperative pain
- High blood pressure
- Agitation
- Hypoxia

This is not a complete list of side effects. For any unexpected effects while taking ULTIVA[®], contact your doctor or pharmacist.

REPORTING SUSPECTED SIDE EFFECTS

To monitor drug safety, Health Canada through the Canada Vigilance Program collects information on serious and unexpected effects of drugs. If you suspect you have had a serious or unexpected reaction to this drug you may notify Canada Vigilance:

By toll-free telephone: 866-234-2345

By toll-free fax 866-678-6789

Online: www.healthcanada.gc.ca/medeffect

By email: CanadaVigilance@hc-sc.gc.ca

By regular mail:

Canada Vigilance National Office
Marketed Health Products Safety and
Effectiveness Information Division
Marketed Health Products Directorate
Health Products and Food Branch
Health Canada
Tunney's Pasture, AL 0701C
Ottawa ON K1A 0K9

NOTE: Should you require information related to the management of the side effect, please contact your health care provider before notifying Canada Vigilance. The Canada Vigilance Program does not provide medical advice

MORE INFORMATION

This document plus the full product monograph, prepared for health professionals can be found at: <http://www.abbott.ca> or by contacting the sponsor, Abbott Laboratories, Limited, at: 1-800-699-9948.

This leaflet was prepared by Abbott Laboratories, Limited

Last revised: January 8, 2009.